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Abstract
Cytosine deaminases of the AID/APOBEC family have a weighty influence on 
human health. These enzymes are part of the innate and humoral immunity; 
they participate in lipid metabolism and muscle development, protect cells 
from viruses and regulate retrotransposition. If the activity of AID/APOBEC de-
aminases is misregulated, they can become “weapons of mass destruction,” 
causing deaminations in unprotected single-stranded DNA regions leading to 
genome-wide mutagenesis. Ultimately, mutations contribute to cell malignancy 
and rapid evolution of cancer cells, helping them to evade the organism’s de-
fense. Also, hypermutable tumor cells develop resistance to anti-cancer drugs. 
Here we overview current understanding of the structure, functions, and regu-
lation of AID/APOBEC cytosine deaminases in connection to carcinogenesis.
Keywords: Cytosine deaminases AID/APOBEC, DNA damage, mutation, cancer. 
Carcinogenesis is often associated with the accumulation of a large number of 
new mutations in somatic cells. In one scenario, driver mutations in proto-onco-
genes or tumor suppressor genes trigger uncontrolled cell proliferation, which is 
often accompanied by a decrease in the accuracy of replication and repair (Loeb 
et al., 1974; Loeb, 2001). In another, the driver mutation can by itself cause a mu-
tator phenotype that leads to mutations in oncogenes and onset of tumorigenesis. 
During tumor growth, its cells accumulate additional mutations, the number of 
which increases after each division. Some of these mutations enhance the tumor 
aggressiveness and cause drug resistance of tumor cells; others are called “pas-
senger mutations” and do not affect carcinogenesis (Stratton et al., 2009; Martin-
corena et al., 2015; Martincorena et al., 2017; Bailey et al., 2018).
Different tumors can differ significantly by the quantity of accrued muta-
tions, mutation types, and their distribution along the genome, which depends 
on the nature of mutagenic processes operating in the specific tumor. Therefore, 
analysis of mutational spectra can serve as a tool to deduce what was the cause of 
mutations in tumors (Rogozin et al., 2003; Alexandrov et al., 2013; Rogozin et al., 
2018). Recently, cytosine deaminases of the AID/APOBEC family have been im-
plicated in etiology in many types of tumors. Enzymes of the AID/APOBEC fam-
ily regularly participate in various cellular processes, from RNA editing to innate 
and humoral immunity, by deaminating cytosine to uracil in DNA or RNA (Con-
ticello, 2008). Genome-wide deamination would cause a genetic catastrophe. The 
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activity of cytosine deaminases in the cell is strictly reg-
ulated and limited to a few mRNA molecules or selected 
genome loci. Aberrant regulation of deaminase activity 
leads to genome-wide deaminations causing catastroph-
ic accumulation of mutations and cancer (Burns et al., 
2013; Roberts and Gordenin, 2014; Rogozin et al., 2019). 
Introduction to deaminases of  
the AID/APOBEC family
At the moment, 11  human enzymes of the AID/ 
APOBEC family are known. They have different tissue-
specific roles. All of them contain a conservative zinc-
dependent cytidine-deaminase catalytic domain (CDA) 
(Samaranayake et al., 2006; Conticello, 2008; Salter et al., 
2016) (Fig. 1). Those enzymes of this family that pos-
sess enzymatic activity catalyze a simple biochemical 
reaction of cytosine to uracil deamination in the single-
stranded RNA or DNA (Fig. 2). The appearance of uracil 
in either RNA or DNA alters the coding properties of 
the nucleic acid molecule, and mutations appear after 
replication (Fig. 3, upper right corner). Also, uracil in 
DNA is a substrate for base excision DNA repair. Dur-
ing repair, apyrimidinic (AP) sites and, further, single-
strand breaks/gaps can occur, which also have a muta-
genic potential (Lada et al., 2007) (Fig. 3). Breaks during 
base excision repair are a prerequisite to the recombino-
genic activity of deaminases (Di Noia and Neuberger, 
2004; Poltoratsky et al., 2004). Closely spaced deami-
nations on opposite DNA strands may lead to double-
strand breaks (Fig. 3, lower right). The catalytic activity 
of some deaminases or deaminase modules, APOBEC2, 
APOBEC4, and N-terminal domain of both APOBEC3B 
and APOBEC3G is not known (Fig. 2).
APOBEC1 (apolipoprotein B mRNA Editing Cata-
lytic subunit 1)  was the first identified member of the 
AID/APOBEC enzyme family performing deamination 
of cytosine in nucleic acids. In 1993, APOBEC1  was 
shown to be the catalytic subunit of a protein-editing 
complex that post-transcriptionally edits apolipoprotein 
B mRNA (Chen et al., 1987; Powell et al., 1987). The com-
plete form of this apolipoprotein containing 4536 amino 
acids (ApoB100) is synthesized in the liver and the small 
intestine cells. Deamination of cytosine to uracil in posi-
tion 6666 of APOB mRNA leads to substitution of CAA 
glutamine codon to UAA stop codon. When modified 
mRNA carrying a premature stop codon is translated, 
a shortened version of APOB is synthesized with a size 
of 48 % of the original form (ApoB48) (Teng et al., 1993; 
Davidson et al., 1995). Thus, in natural conditions, 
APOBEC1 preferably deaminates only one specific cy-
tosine residue in the mRNA, though recently it was 
found that, in addition to apolipoprotein mRNA, 
APOBEC1  can edit 3’UTR regions of 32  different 
mRNAs (Rosenberg et al., 2011). It is possible, thereby 
for APOBEC1 to exert influence upon gene expression 
by microRNA and other ways. When heterologously ex-
pressed in bacteria and yeast, APOBEC1 can deaminate 
genomic DNA, inducing numerous substitutions in CG 
pairs (Harris et al., 2002; Lada et al., 2011a).
Deaminase AID (Activation-induced deaminase) 
initiates the somatic hypermutagenesis (SHM) and 
class-switch recombination of immunoglobulin genes 
(Muramatsu et al., 1999). During SHM, uracil in the 
DNA template of the variable IG regions leads to C → 
T transitions when replicated (Fig. 3). Also, uracil-con-
taining DNA may be repaired by the base excision repair 
(BER) pathway. When uracil-DNA glycosylase (UNG) 
cuts uracil out from DNA the intermediate product, 
transient AP-sites are formed. Unprocessed AP-sites 
block the major replicative DNA polymerases but could 
be bypassed in error-prone fashion by Y-family transle-
sion DNA polymerases (Casali et al., 2006; Lada et al., 
2007). In another pathway of SHM, U:G pairs are rec-
ognized by DNA mismatch repair (MMR), which gen-
erates gaps in the DNA duplex. In B cells, the gaps are 
oddly filled with the participation of inaccurate DNA 
polymerase η (Fig. 3). As a result, numerous and vari-
ous point mutations appear in the variable regions of 
the immunoglobulin genes of activated B-lymphocytes, 
increasing the diversity of the antibodies (Muramatsu et 
al., 2000; Yoshikawa et al., 2002; Papavasiliou and Schatz, 
2002; Di Noia and Neuberger, 2007). Another factor of 
immunoglobulins diversity, class-switch recombination, 
also depends on AID. Uracils, appearing on the border 
of constant regions of immunoglobulin heavy chain 
genes, are excised by BER or MMR, resulting in single- 
and double-stranded breaks that induce recombination 
leading to antibody isotype switching from IgM to IgG, 
IgA or IgE (Muramatsu et al., 2000; Revy et al., 2000; 
Okazaki et al., 2002; Stavnezer and Schrader, 2006; Di 
Noia and Neuberger, 2007).
After the discovery of the role of AID in immunity, 
it was unclear whether it deaminated either DNA or 
RNA (Muramatsu et al., 2000). Seminal experiments by 
Michael Neuberger’s group unequivocally demonstrat-
ed that AID deaminates DNA (Petersen-Mahrt et al., 
2002). The expression of the AID gene in E. coli cells was 
mutagenic, and the effect was much stronger in ung1- 
cells unable to excise uracil from DNA (Petersen-Mahrt 
et al., 2002; Beale et al., 2004). Purified AID deaminated 
single-stranded DNA in vitro, producing clustered mu-
tations with a signature similar to mutations in immu-
noglobulin genes (Pham et al., 2003). Human deaminase 
AID expressed in yeast cells is mutagenic, too (Poltor-
atsky et al., 2004). AID increased the frequency of Canr 
forward mutations almost 8-fold in the wild-type strain 
and 82-fold in the ung1  mutant. The synergistic effect 
was observed for the frequency of reversions of nonsense 
mutation (that occur mainly by suppressor mutations in 
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Fig. 1. Phylogenetic tree of human AID/APOBEC deaminases (Rogozin et al., 2007; Krishnan et al., 2018). Active deaminase modules are shown 
in solid blue, deaminase domains which have no catalytic activity are shown as cross-hatched bars. The numbers above each bar refer to amino 
acid positions according to (https://www.uniprot.org).
Fig. 2. Cytosine deamination performed by AID/APOBEC family deaminases on ssDNA generates U:G mispair.
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the anticodons of tRNA genes) in the ung1 strain, with 
an increase up to 1290-fold over the wild-type. Sequenc-
ing of the CAN1  gene in AID-induced Canr mutants 
revealed that most mutations were transitions in GC 
pairs in a context similar to SHM (Mayorov et al., 2005; 
Rogozin and Pavlov, 2006). Genome-wide studies de-
tected mutational clusters with a predominance of C → 
T transitions (Lada et al., 2012; Taylor et al., 2013).
APOBEC2 is found in the heart and skeletal mus-
cles of mice, chickens, and humans (Liao et al., 1999; Li 
et al., 2014). It is necessary for the normal development 
of muscles and weight gain in mice (Sato et al., 2009). In 
the absence of APOBEC2, animals develop age-depen-
dent myopathy (Sato et al., 2009), which was related to 
mitochondrial function defects (Sato et al., 2017). Het-
erologous expression of APOBEC2 in yeast and bacteria 
did not lead to a mutator phenotype (Lada et al., 2011a), 
and APOBEC2 does not deaminate DNA in vitro (Harris 
et al., 2002; Lada et al., 2011a).
The APOBEC3  (A3)  human deaminase subfam-
ily includes seven proteins: A3A, A3B, A3C, A3DE, 
A3F, A3G, and A3H, possessing one deaminase module 
(A3A, A3C, A3H) or two modules (A3B, A3DE, A3F, 
A3G), (Fig. 1). The genes encoding these proteins are 
located on chromosome 22  in tandem (Jarmuz et al., 
2002). APOBEC3 deaminases protect cells from exoge-
nous and endogenous retroelements by inducing hyper-
mutagenesis in the viral genome. A3B, A3DE, A3F, A3G, 
and A3H inhibit the replication and infectivity of HIV-
1 (Doehle et al., 2005; Chaipan et al., 2013). A3G has 
been shown to inhibit HIV-1/Δvif infectivity through 
the degradation or hypermutagenesis of the viral minus-
strand DNA (Sheehy et al., 2002; Harris et al., 2003). 
A3B, A3F, and A3G prevent infection with the hepati-
tis B virus by introducing numerous CG → TA transi-
tions into the virus DNA (Suspene et al., 2005; Bonvin 
et al., 2006). A3A, A3B, A3DE, and A3H inhibit the Alu 
retrotransposition (Bogerd et al., 2006; Orecchini et al., 
2018). A3A, A3C, and A3H deaminate papillomavirus 
DNA (Vartanian et al., 2008). A3A inhibits replication of 
the adeno-associated virus (AAV), a member of the par-
vovirus family (Chen et al., 2006). A3A, which has one 
deaminase module, can inhibit replication of both wild-
type AAV and the autonomous parvovirus minute virus 
of mice (MVM) by a DNA deamination-independent 
mechanism (Narvaiza et al., 2009). Perhaps deaminase 
binds to viral RNA and sterically inhibits further elon-
gation of reverse transcription (Bishop et al., 2008). In 
this relation, APOBEC1, all APOBEC3 proteins and an-
other member of this family, deaminase AID, inhibit hu-
Fig. 3. Genetic consequences of cytosine deamination in DNA by AID/APOBEC. Altered DNA is shown in red; operating processes are shown in 
blue, enzymatic systems in black and resulting genetic alterations in maroon. U — uracil; AP — apyrimidinic site; N — any base; BER — base 
excision repair; MMR  — mismatch repair; NHEJ  — non-homologous end joining; UNG  — uracil-DNA-glycosylase; APE  — AP endonuclease; 
Pol β — DNA polymerase β; TLS Pols — translesion DNA polymerases; DSB — double-strand DNA break.
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man LINE-1 retrotransposition, and can do it through a 
deamination-independent manner (Bogerd et al., 2006; 
Muckenfuss et al., 2006; Stenglein and Harris, 2006; Ki-
nomoto et al., 2007; Schumann, 2007; Pak et al., 2011; 
Orecchini et al., 2018).
Although the single cytidine-deaminase domain 
of A3A has significant homology with the C-terminal 
domain of A3G (~ 65 %) and A3B (~ 90 %), A3A has 
no antiviral activity against HIV-1  (Goila-Gaur et al., 
2007; Caval et al., 2014). Endogenous A3A is a pre-
dominantly cytoplasmic protein and is not expected to 
be genotoxic (Land et al., 2013), but when upregulated, 
it causes DNA damage (Suspène et al., 2017). Under 
conditions of overexpression, A3A becomes genotoxic 
(Land et al., 2013) and can enter the nucleus (Chen et 
al., 2006). Studies have shown that A3A induction acti-
vates severe DNA damage response (DDR) in a deami-
nase-dependent manner. Ectopic expression of A3A in 
U2OS osteosarcoma cells caused an accumulation of 
phosphorylated histone γ-H2AX, which is a marker of 
double-stranded DNA breaks (Chowdhury et al., 2005; 
Landry et al., 2011). At the same time, phosphorylated 
forms of replication protein A (RPA), activation of ATM 
protein kinase, and cell cycle arrest in the early S phase 
were observed in response to DNA damage (Shiloh, 
2003; Jackson and Bartek, 2009; Landry et al., 2011). 
While a mutant A3A gene encoding a protein without 
deaminase activity was expressed, a cascade of events 
of the response to DNA damage was not triggered. In 
HEK293 cells, overexpression of A3A was also cytotoxic 
(Burns et al., 2013). Recently, it was shown that, besides 
DNA, A3A could deaminate transcripts of 3078  genes 
at more than 4200 sites and change the amino acid se-
quence of 1110  proteins (Sharma et al., 2015; Sharma 
et al., 2017). Those include genes associated with breast 
cancer, hematologic neoplasms, amyotrophic lateral 
sclerosis, Alzheimer disease, and primary pulmonary 
hypertension (Sharma et al., 2017). A3A expression is 
mutagenic in yeast cells (Taylor et al., 2013; Hoopes et al., 
2016). Heterologous expression of the two-domain A3B 
is also mutagenic in E. coli and yeast (Bogerd et al., 2006; 
Taylor et al., 2013). The N-terminal deaminase module 
of A3B does not possess the catalytic activity and is not 
mutagenic, but enhances both the deaminase activity of 
the C-terminal domain and binding to the substrate sin-
gle-stranded DNA (Bogerd et al., 2006; Fu et al., 2015). 
Heterologous expression of A3C and A3G is mutagenic 
in E. coli and yeast (Harris et al., 2002; Schumacher et al., 
2005; Lada et al., 2011a; Taylor et al., 2013).
APOBEC4 deaminase was found bioinformatically 
by analyzing protein sequence databases and is present 
in mammals, chickens, and frogs (Rogozin et al., 2005). 
It weakly interacts with single-stranded DNA, does not 
exhibit deaminase activity in vitro, and enhances the 
replication of HIV-1 (Marino et al., 2016). No mutator 
phenotypes were detected in yeast and bacteria express-
ing APOBEC4 (Lada et al., 2011a).
Deamination and mutagenesis  
by AID/APOBECs
All currently known human AID/APOBECs are struc-
turally similar to each other, but their functions are very 
different. After the breakthrough discovery of deami-
nases, especially AID, the urgent problem was to under-
stand how they realize their catalytic potential in target-
ed genome compartments, in specific cells and tissues. 
Purified AID needs RNase treatment to exert deamina-
tion activity on single-stranded DNA (Bransteitter et al., 
2003); RNA attenuates A3B activity (Xiao et al., 2017), 
suggesting a role of RNA bound to deaminases in the 
regulation of their activity. AID deaminations in single-
stranded DNA in vitro lead to clustered mutations in 
defined DNA sequence contexts (Pham et al., 2003) by 
intertwined scanning and catalysis (Mak et al., 2013). 
Transcription has an essential role in AID activity be-
cause it constantly generates ssDNA (Pham et al., 2003). 
AID causes multiple clustered mutations under tran-
scriptional pausing and stalling (Canugovi et al., 2009). 
Transcription is not the only source of unprotected 
ssDNA, and mutations attributed to APOBECs are 
detected in parity on both transcribed and non-tran-
scribed DNA strands in human tumors (Kazanov et al., 
2015). Yeast cells expressing human AID have revealed 
deamination on both DNA strands with more efficient 
uracil repair in the transcribed DNA strand (Mayorov 
et al., 2005). Genome-wide studies of APOBEC-induced 
mutations in yeast firmly established the connection of 
deamination with transcription (Taylor et al., 2014; Lada 
et al., 2015; Saini et al., 2017). DNA may be transiently 
exposed to APOBEC deaminases during replication 
(Green et al., 2016). Lagging DNA strand replication 
involves more complicated transactions, thus leaving 
unprotected ssDNA more frequently. Not surprisingly, 
a third of mutations attributed to APOBECs are inferred 
to occur during DNA replication on the lagging strand 
in cancer cells (Seplyarskiy et al., 2016). APOBEC-de-
pendent deamination preferentially occurs in the lag-
ging strand in yeast (Hoopes et al., 2016) and E. coli 
(Bhagwat et al., 2016). One additional source of ssDNA 
substrates for deaminases is homologous recombination 
(Poltoratsky et al., 2010; Taylor et al., 2013). 
Double-stranded DNA is resistant to deaminase ac-
tion. Transcription, replication, and repair provide tran-
sient single-stranded regions that can be deaminated. 
Single-strand DNA binding proteins (e.g., RPA) attenu-
ate the ability of APOBECs to work on ssDNA (Pham et 
al., 2008; Lada et al., 2011b). Accessibility of ssDNA to 
RPA versus competing APOBECs determines the extent 
of mutagenic action of deaminases. The sites/situations 
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where the balance is shifted to APOBECs are one of the 
factors for the appearance of hypermutated regions in 
cells. The mutations caused by deaminases are found 
in the regions of the chromosomes that contain a large 
number of genes and are transcribed early (Kazanov et 
al., 2015).
Footprints of deaminases in DNA
Studies in microbial models and analysis of cancer ge-
nomes allowed identification of specific deaminase im-
prints in DNA termed “AID/APOBEC mutational signa-
tures.” A mutational signature is a specific combination 
of base substitutions and other mutations in a defined 
sequence context (Rogozin and Pavlov, 2003). By study-
ing the mutational signatures in cancer cells, it is possi-
ble to deduce with some probability the strength and du-
ration of the action of the mutagenic factor (Nik-Zainal 
et al., 2012). About 30 signatures of various mutational 
processes have now been identified in cancer genomes, 
two of them (no. 2 and no. 13) belong to the APOBEC 
family deaminases, (Nik-Zainal et al., 2012; Alexandrov 
et al., 2013; Alexandrov and Stratton, 2014). APOBEC 
mutational signatures were found in more than half of 
human cancers (Alexandrov et al., 2013). The remnants 
of APOBECs deaminations, C → T transitions and C → 
G transversions in the preferred 5’-TC (A/T)-3’ motifs 
that can be caused by A3A and A3B, were found in 3.8 % 
of multiple myeloma cases, along with translocations oc-
curring in the vicinity of the preferred AID 5’-WRC-3’ 
motifs. Patients with an increased number of such muta-
tions had a poor prognosis (Walker et al., 2015).
The study of 1020 cell lines of various types of can-
cer from the COSMIC (Catalog of Somatic Mutations 
in Cancer) somatic mutation database has revealed 
APOBEC mutational signatures in more than 100  cell 
lines (Jarvis et al., 2018). In 5 % of skin cancer cell lines, 
19 % of lung cancer, and 48 % of breast cancer, mutations 
were found that might have been induced by APOBEC 
deaminases. There was a strong positive correlation be-
tween the abundance of APOBEC signatures in breast 
cancer cell lines with overall base substitution muta-
tion loads (Jarvis et al., 2018). Bladder cancer analysis 
by TCGA (The Cancer Genome Atlas) revealed the 
APOBEC mutational signature in 84 % of bladder cancer 
samples. The expression of both A3A and A3B in blad-
der cancer samples correlated with overall mutation load 
in bladder cancer (Glaser et al, 2018). Mutations in the 
DNA damage response genes (TP53, ATR, BRCA2) and 
chromatin regulatory genes (ARID1A, MLL, MLL3) were 
substantially enriched in the bladder cancer samples with 
the APOBEC signature (Glaser et al., 2018). 
In 2012, another interesting hallmark of deami-
nase action was discovered by the international team 
of researchers of the Wellcome Trust Sanger Institute 
in the analysis of the genomes of breast cancer samples. 
Among multiple scattered mutations, clusters of closely 
spaced mutations were found. The phenomenon was 
named kataegis, from Greek “thunderstorm.” The major-
ity of mutations were CG → TA transitions; therefore it 
was suggested that APOBEC deaminases are connected 
to kataegis (Nik-Zainal et al., 2012). Almost at the same 
time, C- or G-coordinated mutation clusters (multiple 
changes of either “C” or “G” in continuous DNA strand) 
were detected in genomes of multiple myeloma, pros-
tate, and head and neck cancer (Roberts et al., 2012) and 
were linked to APOBEC activity, because of frequent-
ly occurring mutations in TCW (W=A or T) motifs 
characteristic to several APOBEC deaminases (Rob-
erts et al., 2012). Expression of model deaminase genes 
PmCDA1 and AID in yeast resulted in kataegis, too, con-
firming a link between the activity of deaminases and ka-
taegis (Lada et al., 2012; Lada et al., 2013). A3A and A3B 
mutation specificity in yeast was similar to mutations 
found in some breast cancers; kataegistic clusters de-
pended on DSBs (Taylor et al., 2013). Kataegis is defined 
as the proximity of six or more mutations with an average 
intermutation distance less than one kb in the same DNA 
strand (Nik-Zainal and Morganella, 2017). Mechanisti-
cally, kataegis might be explained by the appearance of 
continuous single-stranded regions during transcription 
or repair of double-stranded DNA breaks or break-in-
duced replication (Sakofsky et al., 2014). Kataegis is often 
observed in junction regions of chromosomal rearrange-
ments in human tumor cells. Typically, the APOBEC sig-
nature consists of C → T transitions in the characteristic 
motifs and C → G transversions, which result from the 
operation of translesion polymerases on the damaged 
strand with an AP site (Taylor et al., 2013; Hoopes et al., 
2017). The similarity in specificity and distribution of 
mutations induced by deaminases in model systems and 
found in tumors indicate that AID/APOBEC deaminases 
play a significant role in cancer origin and development.
The role of AID/APOBECs in  
the etiology of cancer
Discovery of deaminases led to a prediction that lack 
of control over deaminases in the cell might lead to ge-
nome-wide mutagenesis and cancer (Neuberger et al., 
2003). The hypothesis quickly found experimental sup-
port from studies with model systems discussed above 
and evidence from analysis of human cancers; this led to 
the tremendous expansion of a number of publications 
on the roles of various deaminases in carcinogenesis 
(Rogozin et al., 2018).
Hepatic dysplasia and hepatocellular carcinoma were 
observed in transgenic mice and rabbits with constitutive 
expression of APOBEC1 (Yamanaka et al., 1995). With 
the constitutive expression of APOBEC2  in transgenic 
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mice, liver and lung cancer developed, and changes in 
the RNA nucleotide sequence of some oncogenes were 
also found (Okuyama et al., 2011). Transgenic mice with 
constitutive expression of AID developed malignant 
T-cell lymphomas, and micro-adenomas/adenocarcino-
mas in the lung, hepatocellular carcinomas, gastric can-
cer; in parallel, point mutations in T-cell receptors, MYC, 
KRAS, TP53  genes were frequently observed (Okazaki 
et al., 2003; Morisawa et al., 2008). Aberrant activity of 
AID can trigger double-stranded DNA breaks not only in 
immunoglobulin genes but in other susceptible genomic 
regions, which leads to chromosomal translocations be-
tween immunoglobulin genes and other genes. During 
such events, proto-oncogenes translocate to cis-regulato-
ry transcriptional elements and strong immunoglobulin 
enhancers that cause unregulated constitutive expression 
of the translocated gene (Ramiro et al., 2004; Robbiani et 
al., 2009; Nussenzweig and Nussenzweig, 2010). Such re-
arrangements are the hallmark of lymphomas (Okazaki 
et al., 2007). AID is implicated in the hypermutagenesis 
of oncogenes controlling proliferation and apoptosis—
MYC, PIM1, JUND, and BCL2—and B cell development 
and activation genes—PAX5, CD79b, AICDA, IRF8, 
BACH2, and NFKB—as well as promoters and super-en-
hancers regulating the cell cycle and apoptosis (Gaidano 
et al., 1997; Qian et al., 2014). Studies have shown that 
there are over a hundred of such genes (Casellas et al., 
2016). Normally, AID activity is restricted to the activated 
B-lymphocytes and some tissues, but in most lymphomas, 
the expression of this deaminase is constant (Okazaki et 
al., 2007).
Analysis of the expression level of various deami-
nases in breast cancer has revealed that 38–70 % of tissue 
samples and cell lines have an increase in the expression 
of APOBEC3B, but not other deaminases of this family. 
These cell lines have twice as many mutations as those 
that express low levels of A3B expression and an increase 
of C → T transitions. Knockdown of A3B caused a de-
crease in the total number of transitions (Burns et al., 
2013). Therefore, it was concluded that A3B is the lead-
ing source of mutations in breast cancer. Further studies 
of 19 types of cancer according to The Cancer Genome 
Atlas (TCGA) revealed an elevated A3B level in head 
and neck, bladder, cervix, and lung cancers, also with 
C → T predominance in the context of 5’-TC-3’, which 
is characteristic of APOBEC3 deaminases (Burns et al., 
2013). In some types of cancer, these mutations reached 
68 % of all mutations (Roberts et al., 2013). In the case 
of estrogen-positive breast cancer, expression of A3B is 
associated with poor prognosis during treatment. A3B 
regulates the estrogen receptor, enhances tumor growth 
and confers resistance to treatment with tamoxifen 
(Periyasamy et al., 2015; Law et al., 2016). 
Some experimental evidence, however, argues 
against the overwhelming dominance of A3B in cancer 
etiology. It turned out the human genome has the com-
mon deletion polymorphism on chromosome 22 in the 
APOBEC3 subfamily gene locus (Kidd et al., 2007). Car-
riers of the deletion allele lack a 29.5  kb fragment be-
tween the fifth exon of A3A and the eighth exon of A3B, 
and cells produce a transcript containing the 3’-untrans-
lated region (3’-UTR) from A3B and the coding part 
identical to the A3A gene. The main difference between 
the 3’-UTR of the two genes is that the A3A 3’-UTR 
contains Alu-repeat (Kidd et al., 2007). The deletion is 
rare in Europe (9 %) and Africa (0.9 %), more common 
in Asia (36.9 %) and America (57.7 %), and almost ubiq-
uitous in Oceania (92.9 %) (Kidd et al., 2007). Contrary 
to the expectations, breast cancer rates are comparable 
in all these regions. Also, the polymorphism is more 
common in European and Chinese women with breast 
cancer, than in healthy ones (Xuan et al., 2013). The total 
number of mutations in the genomes of breast cancer 
cells is increased in cells with deletion polymorphism 
(Nik-Zainal et al., 2014). The A3A-UTRA3B chimeric 
transcript expressed in HEK293T cells increases both the 
chimeric A3A mRNA level yielding 10–20-fold and the 
deaminase activity A3A in comparison to A3A-UTRA3A. 
Therefore, it was concluded that the expression level of 
A3A is regulated by the 3’-UTR region. The chimeric 
protein also caused more damage and double-stranded 
breaks than the naturally occurring A3A, which ex-
plained the association of deletion polymorphism with 
a large number of mutations in cancer cells (Caval et al., 
2014). It became apparent that A3B is not the only factor 
in mutagenesis conferred by deaminases in cancer.
APOBEC3A can be more cytotoxic and genotoxic 
than APOBEC3B (Caval et al., 2015). In yeast cells, it was 
possible to establish a difference in the preferred deami-
nation motifs, YTCA for A3A and RTCA for A3B (Y = 
pyrimidine, R = purine), and thereby determine what 
proportion of tumors possess A3A versus A3B signa-
tures (Chan and Gordenin, 2015). It is uniformly agreed 
that A3A overexpression can cause double-stranded 
DNA breaks and apoptosis, but there is controversy in 
the case of A3B (Landry et al., 2011; Burns et al., 2013; 
Taylor et al., 2013; Caval et al., 2014). The study of the 
relative roles of A3A and A3B in cancer needs further 
thorough investigation. 
Factors affecting the activity of  
AID/APOBEC deaminases
The normal expression of AID/APOBECs is tissue-spe-
cific in humans (Conticello, 2008; Salter et al., 2016). 
We know that the heterologous expression of deaminase 
genes in bacterial and yeast cells leads to an increase in 
the frequency of mutations (Harris et al., 2002; Lada et 
al., 2011a). High levels of deaminases are potentially 
harmful, though the correlation between deaminase lev-
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els and actual deamination is complicated (Siriwardena 
et al., 2018) and the activity of deaminases in human 
cells is under tight control. When the deaminase activ-
ity regulation is compromised, the enzymes deaminate 
cytosine in nonspecific loci of the genome, which leads 
to an increase in the frequency of mutagenesis and ma-
lignant transformation of tissues (Yoshikawa et al., 2002; 
Ramiro et al., 2004; Robbiani et al., 2009; Roberts et al., 
2013). The search for factors affecting deaminase activ-
ity might help identify new risk factors and methods for 
the prevention and treatment of cancer.
Both bacterial lipopolysaccharides and human 
papillomavirus‐like particles induce AID expression in 
murine B cells (Okazaki et al., 2007). Epstein-Barr virus 
and hepatitis C virus induce AID expression in B‐lin-
eage cells (Okazaki et al., 2007). Chronic inflammation 
on the background of cancer or virus infection leads to 
the release of cytokines TGFβ, TNFα, IL-4, IL-13, which 
initiate the expression of AID and cause the subsequent 
mutation of the tumor suppressor TP53 and other genes 
and solid tumor development (Kumar et al., 2014; 
Choudhary et al., 2017). Studies show that in chronic in-
flammation and hypoxia, the risk of developing cancer 
is increased due to an elevated level of A3A and the sub-
sequent enhancement of RNA editing by this protein, 
since the expression of A3A and A3B is stimulated by 
interferons (Bonvin et al., 2006; Sharma et al., 2017). In-
creasing the amount of these proteins is one of the stages 
in the development of the immune response to infection 
with viruses. Infection of breast and bladder cancer cell 
lines with Sendai virus led to a strong induction of A3A, 
but more moderate induction of A3B, possibly because 
of the initially high expression of A3B deaminase in can-
cer cells (Middlebrooks et al., 2016).
Cancer cells multiply faster than normal with fer-
vent replication. Therefore, the number of mutations in 
tumors increases with time (Hanahan and Weinberg, 
2011). Permanent divisions deplete protein complexes 
that ensure the stable progression of the replication fork. 
Many oncogenes induce replication stress, defined as the 
impediment of replication, which also contributes to the 
accumulation of mutations. The number of sites with 
unprotected ssDNA increases, creating favorable con-
ditions for APOBEC mutagenesis (Cescon and Haibe-
Kains, 2016; Hoopes et al., 2016). Anti-cancer drugs 
camptothecin, gemcitabine, hydroxyurea, and the DNA 
polymerase inhibitor α-aphidicolin also induce replica-
tion stress. The stress increases the activity of deaminas-
es A3A and A3B (Kanu et al., 2016). 
It has been suggested that the regulation of the ex-
pression of A3A and A3B may also occur at the post-
transcriptional level using miRNA. The 3’-UTR A3A is 
674 bp long. Hundreds of potential microRNA binding 
sites were found in the 3’-UTR of A3A. In the 3’-UTR 
of A3B with a length of 356 bp 82 potential microRNA 
binding sites were predicted. It is possible that the re-
pression of A3A by miRNA will be tighter than A3B or 
chimeric A3A-UTRA3B (Cao and Wu, 2017). Also, four 
kinds of miRNA bind to target sites in the AID 3’-UTR 
and reduce the amount of the protein (Zan and Casali, 
2013). Modulation of APOBEC gene expression by miR-
NA might be a perspective method of modulation of de-
aminase activity in cancer. 
There is no doubt that deaminases of the AID/ 
APOBEC family contribute significantly to tumor ori-
gins and progression. We expect that many puzzles and 
mysteries related to cancer/deaminases connection that 
surfaced during the first two decades of research in the 
field will be subject to intense future studies.
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